Picture of NeoGenomics logo

NEO — NeoGenomics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Neogenomics Inc expected to post a loss of 2 cents a share - Earnings Preview

* Neogenomics Inc  NEO.OQ   NEO.O  is expected to show a
rise in
quarterly revenue when it reports  results on February 20 for
the period ending December 31 2023
    * The Fort Myers Florida-based  company is expected to
report a
10.0% increase in revenue to $152.535 million from $138.71
million a year ago, according to the mean estimate from 12
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Neogenomics Inc is for a
loss
of 2 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Neogenomics
Inc
is $19.00​, above​ its last closing price of $14.90. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.06       -0.07      0.00      Beat    100
 Jun. 30 2023  -0.11       -0.11      -0.05     Beat    56
 Mar. 31 2023  -0.15       -0.15      -0.09     Beat    40.5​
 Dec. 31 2022  -0.15       -0.16      -0.06     Beat    63.6
 ​​Sep.        -0.20       -0.21      -0.14     Beat    32
 30 2022                                                
 Jun. 30 2022  -0.20       -0.23      -0.16     Beat    29​
 Mar. 31 2022  -0.24       -0.24      -0.20     Beat    15
 Dec. 31 2021  -0.14       -0.15      -0.14     Beat    3.8
 This summary was machine generated February 16 at 23:07 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on NeoGenomics

See all news